Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
Back
Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME
Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
3
After Sickle Cell Gene Therapy, What Comes Next?
4
New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot
5